A study may have just potentially found a new way of treating and even curing prostate cancer with the help of specific hormone high doses and then complete deprival.
The experimental study was carried out by a team of Baltimore’s Johns Hopkins University School of Medicine. The results of the study led by Professor Sam Denmeade were presented during the Munich-based Molecular Targets and Cancer Therapeutics symposium.
Research sought to investigate the effects of the testosterone hormone in the treatment of prostate cancer.
The hormone is believed to be amongst this specific cancer’s fuels with most current prostate cancer treatments trying to minimize its levels.
As such, the results of the small testosterone trial were all the more surprising. Amongst the current 47 trial patients, one former sufferer has seen his cancer disappear.
The majority of the remaining patients have also marked a significant decrease in the progression rate of the disease.
All of the trial patients have been diagnosed with advanced prostate cancer. They were also determined to have been suffering from abiraterone and enzalutamide resistant cancer forms.
The two aforementioned hormones are amongst the latest therapy drugs used in treating the disease. As most current treatments are seeking to starve the disease of its hormone fuel, it was noticed that the tumors can become resistant to the treatment.
Previous lab studies have also shown that the same hormone, but in high levels, could help suppress or even possibly kill the prostate cancer cells.
During the experimental treatment, the 47 participants were subjected to more than 3 BAT or bipolar androgen therapy cycles.
The BAT is the name given to a treatment method that alternates starving and flooding the patient’s body with testosterone.
Whilst the patients were injected with high doses of testosterone each and every 28 days, they were also given a hormone suppressing drug.
As such, once the effects of the injection wore down, the men would no longer have testosterone as their natural production was suppressed.
The results of the method were tested by measuring the size of the sufferers’ tumors and also by following the PSA levels. The PSA levels are the Prostate Specific Antigen cancer marker.
Amongst the patients, one who has been following the therapy for almost two years as he has come to pass through 22 cycles, saw his disease disappear.
The general numbers of the experiment showed that the PSA levels marked a decrease in about 40 percent of the patients.
Amongst them, 30 percent saw a fall of more than a half as compared to their initial PSA levels. As such, many have seen their disease stagnate for over more than 12 months.
Observations have also shown that the patients to have passed through the BAT cycles seem to have also become more susceptible to the available treatments.
As their cancer form was previously resistant to such drugs, the method could come to also be used as an alternative for such cases.
The experimental study is a still on-going trial with more patients being expected and hoped for. A full set of results will not be available until the study will be finalized.
However, the study shows promising results and could mark a new prostate cancer treatment method.
Image Source: Wikimedia